This comes at a time when Kenya's HIV prevalence stands at 3.7 per cent, with approximately 1.34 million people on antiretroviral therapy.
Of concern, Dr Amoth noted, is the fact that 41 per cent of new HIV infections among young people below the age of 24 years, underscoring the urgent need for novel prevention measures.
The medicine had earlier been approved by the United States Food and Drug Administration in June 2025 and endorsed by the World Health Organisation a month later.
The Pharmacy and Poisons Board recommended the product for registration in January this year, following a scientific review.
Kenya was selected among the first nine countries in Africa to receive it in July 2025
Brian Rettman, Chief Program Officer at the American Embassy, described the shipment as a significant advancement in prevention efforts.
"Lenacapavir is going to be a very instrumental piece in providing HIV prevention in the country," he said.
He added: "It's an injection someone takes two times a year and receives full protection, just like the daily pills previously taken."
The initial supply, the Ministry said, has been secured through support from the Global Fund under a negotiated arrangement that reduced the cost to approximately Sh7,800 per patient per year-down from an original annual price of about $42,000 at product introduction.